A Phase 1/2 interventional study of Placebo and AEF0217 in Down Syndrome, sponsored by Aelis Farma. Completed at 3 sites in Spain. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-10-10.
Sponsored by Aelis Farma · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Down Syndrome with a site in Spain — 9 open to participants now, 9 under way, 1 of them phase 3. Down Syndrome · Spain.
Among the 36 studies in Down Syndrome with a site in Spain, this one is the 11th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 1/2, and was the 25th registered.
439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.
Browse Down Syndrome studies →9 of the 36 studies in Down Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Spain, United States
Ages 40–55
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Aelis Farma · Sites in Spain, France, Italy
Ages 16–32
University of Seville · Sites in Spain
Ages 1 mo–18 mo
University of Seville · Sites in Spain
Ages 4–30
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1
First in 2009; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 38 across 287 interventional studies indexed under Down Syndrome.
Median enrollment 58 across the 18 interventional studies, 113 across the 18 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 36 have an industry lead sponsor. The 10 most frequent:
Aelis Farma is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Aelis Farma has 3 studies filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Down Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
AEF0217-102 clinical trial assesses the safety, tolerability, plasma exposure and preliminary indications of pharmacodynamic activity of AEF0217 in female and male adult participants with Down syndrome between 18 and 35 years old.
The trial AEF0217-102 is a double-blind, randomized, placebo-controlled, multiple-dose, 4-week phase 1/2 study. After a screening period, the participant will be randomised and will take an oral dose of AEF0217 0.2mg or placebo once a day for 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs, (ECG), and safety laboratory parameters must be within normal ranges or without abnormalities except for:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AEF0217 0.1 mg tablet 2 tablets in 10 ml of water per day during 28 days
Drug: AEF0217
Placebo tablet 2 tablets in 10 ml of water per day during 28 days
Drug: Placebo
Matching Tablets
Tablets of 100 mcg AEF0217
Also known as: 3β-benzyloxy-17α-methyl-pregn-5-en-20-one
Incidence of TEAEs and TESAEs as assessed by ElectroCardioGram (ECG)
By evaluating changes from the baseline in ECG parameters
Time frame: Day1, Day 8, Day14, Day21, Day29, Day56
Incidence of TEAEs and TESAEs as assessed by vital signs
By evaluating changes from the baseline in vital signs
Time frame: Day1, Day4, Day 8, Day14, Day21, Day27, Day 28, Day29, Day42, Day56
Incidence of TEAEs and TESAEs as assessed by Laboratory clinical parameters
By evaluating changes from the baseline in clinical laboratory values from blood and urine samples.
Time frame: Day1, Day 8, Day14, Day21, Day29, Day56
Incidence of TEAEs or TESAEs
Assessed by AE and SAE reporting
Time frame: From Day1 to Day56
Potential effects of AEF0217 on cognition using the NIH-ToolBox for ID corrected fluid cognitive
Change from baseline in the corrected fluid cognition composite t-score of the NIH-ToolBox for ID Change from baseline in the scores of each of the individual 5 tests constituting the fluid cognition composite score
Time frame: Day1, Day27
Determination of the minimum plasma concentration of AEF0217 before dosing (cthrough)
AEF0217 concentration will be determined. Ctrough (at steady state) will be estimated based on the plasma concentration-time profile of AEF0217.
Time frame: Day1, Day4, Day8, Day14, Day21, Day22, Day29, Day42, Day56
Determination of the peak plasma concentration of AEF0217 (Cmax)
AEF0217 concentration will be determined based on the plasma concentration-time profile of AEF0217 and AEF0217 PK parameter Cmax will be estimated.
Time frame: Day1, Day4, Day8, Day14, Day21, Day22, Day29, Day42, Day56
Determination of the Time of peak concentration of AEF0217 (Tmax)
AEF0217 concentration will be determined and AEF0217 PK parameter Tmax will be estimated.
Time frame: Day1, Day4, Day8, Day14, Day21, Day22, Day29, Day42, Day56
Determination of the plasma half-life of AEF0217 (t1/2)
AEF0217 concentration will be determined and AEF0217 PK parameter t1/2 will be estimated.
Time frame: Day1, Day4, Day8, Day14, Day21, Day22, Day29, Day42, Day56
Determination of the Area under the plasma concentration versus time curve of AEF0217 (AUC)
AEF0217 concentration will be determined, based on the plasma concentration-time profile of AEF0217 and AEF0217 PK parameter AUC will be estimated.
Time frame: Day1, Day4, Day8, Day14, Day21, Day22, Day29, Day42, Day56
Effect on ElectroEncephaloGram (EEG) parameters
Difference between active and placebo at Day 28 in the following EEG parameters: * Gamma intertrial coherence (ITC) during an ASSR at 40 Hz. * Interhemispheric connectivity (IHC) in resting state (eyes open/closed): Band coherence, phase lag index (PLI). * Event-related potential (ERP) associated to novel stimuli in the parietal midline (Pz) during the 3-stimuli oddball task. * Cognitive workload and working memory EEG features during the working memory test of CANTAB (Spatial Span Test)
Time frame: Day28
Responses to treatment according to APOE genotypes.
Determination of the APOE ε4 carriers and non-carriers. Analysis in sub-category
Time frame: Day 56
To explore effects on additional ElectroEncephaloGram parameters
Difference between active and placebo at Day 28 in the following EEG parameters: * Power during an ASSR at 40 Hz. * Phase-amplitude coupling and clustering coefficient in resting state (eyes open/closed).
Time frame: Day28
Ran from Dec 2022 to primary completion in Oct 2024, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AEF0217
Aelis Farma